ArticleIranian Red Crescent medical journal2016
Expression and Clinical Significance of Tumor Necrosis Factor Receptor-Associated Factor 6 in Patients With Colon Cancer.
Article in Iranian Red Crescent medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Targeting TRAF6/IRF3 axis to inhibit NF-κB-p65 nuclear translocation enhances the chemosensitivity of 5-FU and reverses the proliferation of gastric cancer.Cell death & disease · 2024Article
- Tumor Necrosis Factor Receptor-Associated Factor 6 and Human Cancer: A Systematic Review of Mechanistic Insights, Functional Roles, and Therapeutic Potential.Journal of Cancer · 2024Review
- POU5F1 promotes the proliferation, migration, and invasion of gastric cancer cells by reducing the ubiquitination level of TRAF6.Cell death & disease · 2023Article
- Associations of Gastrointestinal Tract Tumor Necrosis Factor Receptor-Associated Factor 6 Expression with Clinical Features and Prognosis of Eosinophilic Gastroenteritis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- The roles of E3 ubiquitin ligases in cancer progression and targeted therapy.Clinical and translational medicine · 2023Review
- miR-146b-5p promotes colorectal cancer progression by targeting TRAF6.Experimental and therapeutic medicine · 2022Article
- TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host.Frontiers in immunology · 2021Article
- MicroRNA-124 regulates TRAF6 expression and functions as an independent prognostic factor in colorectal cancer.Oncology letters · 2019Article
- The Role of Ubiquitination in Regulating Embryonic Stem Cell Maintenance and Cancer Development.International journal of molecular sciences · 2019Review
- Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling.Nature communications · 2019Article
- Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation.Journal of experimental & clinical cancer research : CR · 2018Article
- TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma.Journal of cellular and molecular medicine · 2018Article
- Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.Oncogene · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor necrosis factor receptor-associated factor 6 (TRAF6) has been reported to be highly expressed in many tumor tissues, but it is still of value to detect its expression in patients with colon cancer and to clarify its clinical significance.
objectivesTo study the expression and clinical significance of TRAF6 in patients with colon cancer. PATIENTS AND
methodsA total of 135 patients with colon cancer who underwent surgery at our hospital from February 2008 to March 2013 were selected. The expression levels of TRAF6 protein in tumor and paracancerous tissues were detected with the immunohistochemical method to evaluate their clinical significance.
resultsThe positive expression rate of TRAF6 in tumor tissues was 66.7%, which was significantly higher than in normal paracancerous tissues (18.5%). The positive expression rate of TRAF6 was significantly correlated with Dukes' staging, degree of differentiation, and lymphatic metastasis (P < 0.05), but not gender or age (P > 0.05). The expression level of TRAF6 was negatively correlated with the 5-year survival rate; patients with high TRAF6 expression levels had significantly decreased survival compared to those with low levels (P < 0.05).
conclusionsTRAF6 plays an important role in the onset of colon cancer; therefore, drugs targeting it may have great clinical significance in the treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.